Galápagos CEO Paul Stoffels on the company's $3.8B cash balance and decentralized CAR-T program

blonca9
Jan 9, 2024
1 min read

Paul Stoffels describes how his company's decentralized CAR-T process is designed to have a shorter 'brain-to-vein' time, and he comments on the company's substantial cash balance.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Galápagos CEO Paul Stoffels on the company's $3.8B cash balance and decentralized CAR-T program

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight